275 related articles for article (PubMed ID: 33847973)
1. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
3. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
4. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
5. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
6. The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.
Abou-Al-Shaar H; Mallela AN; Patel A; Shariff RK; Shin SS; Choi PA; Faraji AH; Fazeli PK; Costacou T; Wang EW; Fernandez-Miranda JC; Snyderman CH; Gardner PA; Zenonos GA
Pituitary; 2022 Jun; 25(3):508-519. PubMed ID: 35467273
[TBL] [Abstract][Full Text] [Related]
7. Surgical management considerations in cystic prolactinomas-a single center case series.
Nevzati E; Chatain GP; Carr SB; Lillehei KO; Kerr JM
Endocrine; 2020 Jan; 67(1):58-66. PubMed ID: 31773633
[TBL] [Abstract][Full Text] [Related]
8. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
[TBL] [Abstract][Full Text] [Related]
9. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
11. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
12. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
13. [Predictive value of the Knosp classification in grading the surgical resection of invasive pituitary macroadenomas. A prospective study of 23 cases].
Enseñat J; Ortega A; Topcewski T; Vilalta J; Obiols G; Mesa J; Sahuquillo J
Neurocirugia (Astur); 2006 Dec; 17(6):519-26. PubMed ID: 17242839
[TBL] [Abstract][Full Text] [Related]
14. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas.
Park JY; Choi W; Hong AR; Yoon JH; Kim HK; Jang WY; Jung S; Kang HC
Pituitary; 2021 Dec; 24(6):955-963. PubMed ID: 34189717
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
Giese S; Nasi-Kordhishti I; Honegger J
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
[TBL] [Abstract][Full Text] [Related]
16. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic Endonasal Transsphenoidal Surgery for Patients with Prolactinomas: Indications and Outcomes.
Force BK; Staggers K; Sebastian S; Takashima M; Yoshor D; Samson SL
World Neurosurg; 2022 Dec; 168():e626-e635. PubMed ID: 36270592
[TBL] [Abstract][Full Text] [Related]
18. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
19. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
[TBL] [Abstract][Full Text] [Related]
20. Surgery for prolactinomas: a better choice?
Honegger J; Nasi-Kordhishti I; Aboutaha N; Giese S
Pituitary; 2020 Feb; 23(1):45-51. PubMed ID: 31853793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
